GSK (GSK) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.26 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 9.48%. A quarter ago, it was expected that this drug developer would post earnings of $1 per share when it actually produced earnings of $1.09, delivering a surprise of 9%. Over the last four quarters, the company has surpassed ...

British pharmaceutical company GSK (NYSE: GSK ) reported its third quarter (Q3 2024) and nine months 2024 (9m 2024) results earlier today, which indicate that it's on track to achieve the full-year targets. This is even as Q3 2024 figures showed softening. Here, I Manika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the gree ...

KEY TAKEAWAYS GSK's shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lowerthan-estimated quarterly sales and lowered its projection for vaccine sales. The company reported third-quarter sales of 8.01 billion pounds ($9.59 billion), down 2% year-over-year on lower vaccine sales and below consensus estimates of analysts polled by Visible Alpha of 8.09 billion pounds. The U.K. firm, whose vaccines include Arexvy and Shingrix, now expects 2024 vaccine sales to decrease ...

-- Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of nonadjuvanted bivalent RSV vaccine candidate (SCB-1019) -- -- RSV neutralizing antibodies for Clover's non-adjuvanted SCB-1019 matched GSK's AS01E-adjuvanted AREXVY in older adults, while demonstrating significantly better tolerability compared to AREXVY -- -- Clover plans to initiate clinical trials in 2025 evaluating SCB-1019 in an RSV re-vaccination setting and as part of a respiratory combination va ...

IDE275 (GSK959) development is progressing into First-in-Human Phase 1 clinical trial(s) for the treatment of MSI-High solid tumors, representing IDEAYA's 5th potential first-in-class clinical program MSI-High prevalence in endometrial, colorectal, and gastric cancers is ~31%, 20%, and 19%, respectively, highlighting the market potential of IDE275 (GSK959) IDEAYA to receive a $7 million payment for IND acceptance, and potential future aggregate milestones of up to $950 million. IDEAYA has a 50/50 US Profit ...

GSK plc (NYSE: GSK ) is a biopharmaceutical company with a long history of driving innovation in developing vaccines, specialty medicines, and general healthcare. The company has important products such as Shingrix and Arexvy in its vaccine segment. GSK also presents a strong My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, ...

GSK plc (GSK) announced that the FDA has accepted its new drug application (NDA) seeking approval for its investigational, first-in-class oral antibiotic, gepotidacin for treating uncomplicated urinary tract infections (uUTIs) in female adults and adolescents. With the FDA granting a priority review to the NDA, a decision from the regulatory body is expected on March 26, 2025. If approved, gepotidacin could become the first in a new class of oral antibiotic medicines to be approved for treating uUTIs in mor ...

Group 1: Novavax Update - The FDA has placed a clinical hold on Novavax's combination and standalone influenza shot [1] - Novavax's stock has dropped 17.7% to $10.36, nearing its lowest close since mid-May, although it remains up 115% in 2024 [2] Group 2: Moderna's Market Position - Moderna's shares are trading at $57.42, close to a four-year low of $55.70, reflecting a year-to-date decline of 42.2% [3] - The decline is attributed to a significant budget cut and lowered expectations for its RSV drug, with plans to regain market share by 2025 [3] Group 3: GSK Developments - GSK's stock is up 0.5% to $39.17 following the FDA's acceptance of its new drug application for urinary tract infections [4] - The company received FDA approval for its RSV vaccine in the summer, although the stock did not react significantly, and shares are 5.8% higher in 2024 [4]

GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of John Baldoni, Ph.D., to its Scientific Advisory Board. Dr. Baldoni brings over four decades of experience in the pharmaceutical industry, including leadership roles in scientifi ...

Share price of the British pharmaceutical company GSK (NYSE: GSK ) has gone nowhere since I last wrote about at the end of July. Until yesterday, that is, when it spiked by ~6% following news that the company had Manika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green economy. Her investing group, Green Growth Giants ...